Aureus Pharma licenses AurWEB to Origenis

Paris, FRANCE, September 2006 - Aureus Pharma a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces that Origenis, a Swiss-German based company who offers creative services in drug design, synthesis and characterization has become the first customer subscribing to its AurWEB portal.

Wall Street Reporter presents Origenis

Munich, Germany, July 2006 - Dr. Michael Thormann, Managing Director and Co-Founder, talks about Origenis in an interview with Wall Street Reporter (WSR).

Origenis extends Research Alliance with Alcon
to develop novel ophthalmic compounds

Munich, Germany, June 2006 - Origenis GmbH today announced that it has extended the research alliance with Alcon Research, Ltd. to develop small molecule drugs against important ophthalmic targets for two years. The alliance combines Origenis' compound design and synthesis capabilities with Alcon's applied biology expertise, screening capabilities and development expertise.

Origenis presents at Spotfire Conference

Amsterdam, Netherlands, May 2006 - Origenis presents its proprietary multiparametric process for Drug Design, Synthesis and Characterisation at the Sportfire User Conference.

Origenis starts its operations

Munich, Germany, October 2005 - Origenis starts successfully its operations, after a management buy-out of the former technology group of Morphochem AG.